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Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease. Adiponectin is an adipocyte-derived cytokine
with anti-inﬂammatory, antidiabetic, and antiatherogenic properties. No study has reported on the association between
adiponectin (ADIPOQ) gene and SLE. Our aim is to investigate the association between single-nucleotide polymorphisms in
ADIPOQ gene and SLE. We examined 179 SLE patients and 237 age- and gender-matched controls from Sichuan province
in China. Genotypes were determined using polymerase chain reaction-restriction fragment length polymorphism and DNA
sequencing. Results show that there was no signiﬁcant diﬀerence in the allele frequencies of rs1501299 (P = .311, OR = 1.17, 95%
CI: 0.86–1.59) and rs2241766 (P = .929, OR = 0.99, 95% CI: 0.74–1.33) in ADIPOQ gene between SLE patients and controls.
The same results were seen in their genotypes (P<. 05). The allele frequencies of rs1501299 and rs2241766 polymorphisms of
ADIPOQ may not be associated with SLE risk.
1.Introduction
Systemic lupus erythematosus (SLE) is a multisystem, com-
plex autoimmune disease characterized by autoantibody
production and tissue injury. The formation of immune
complexes with these autoantibodies and their deposition in
multiple organs contribute to eventual end-organ damage.
The disease commonly aﬀects young women and occurs
with diﬀerent frequencies in racial and ethnic groups [1,
2]. Although many studies have shown that environmental
and genetic factors contribute to SLE, its etiopathogenisis
remains unclear [3, 4].
Adiponectin, a product of the adiponectin (ADIPOQ)
gene, is the most abundant human adipose-speciﬁc protein
[5]. It belongs to a family of adipocytokines, including
adiponectin, leptin, resistin, and visfatin [6]. Adipocytokines
are soluble mediators derived mainly from adipocytes and
are thought to play an important role in inﬂammation
and immunity [7]. Diﬀerent adiponectin levels were found
to be related to risks of type 2 diabetes, atherosclerosis,
and coronary artery disease, among others [8, 9]. Similarly,
plasma, urine, and renal levels and expression of adiponectin
were found to be associated with insulin resistance, body
mass index, c-reactive protein, and nephritis in patients with
SLE [10, 11]. Although adiponectin has been suggested as a
biomarker for SLE and SLE nephritis, other potential factors
may prompt its elevation in SLE [12]. Thus, adiponectin has
not been validated as a true SLE biomarker.
A group of researchers recently found that plasma
adiponectin levels are signiﬁcantly lower in obesity, type 2
diabetes, hypertension, atherosclerosis, and other diseases
[13], while in SLE, diabetic nephropathy, and chronic renal
failure, the plasma and urine levels of adiponectin are
signiﬁcantly raised [11, 14]. These phenomena exist for a
number of reasons. First, insulin resistance in obesity, type
2 diabetes, hypertension, atherosclerosis, and other diseases
is a process of attaining a state of energy equilibrium. Low
serum adiponectin levels can be viewed as a pathophys-
iological process in the initial event of insulin resistance.
The negative energy balance of insulin resistance in SLE
can stimulate the secretion of adiponectin to overcome
the inhibiting factor, and serum adiponectin levels increase2 Journal of Biomedicine and Biotechnology
signiﬁcantly. Second, proteinuria in SLE patients causes
simultaneous loss of large amounts of plasma albumin,
certain immunoglobulin, complement components, and
metal-binding proteins. This loss may cause degradation
of the adiponectin enzymes and clear adiponectin disorder.
Third, as a protective cytokine, adiponectin may reduce the
metabolic disorder and endothelial vascular injury caused by
other risk factors in SLE patients. It stimulates secretion of
adiponectin to overcome the inhibiting factor, so that serum
adiponectin level is signiﬁcantly raised.
Adiponectin levels have a strong genetic component,
with an additive genetic heritability of 46% [15]. The
ADIPOQ gene consists of three exons and two introns
spanning a 17-kb region and has been located on chromo-
some 3q27 [16]. The ADIPOQ gene was found to be the
only major gene responsible for plasma adiponectin [17].
While majority of studies on ADIPOQ gene polymorphisms
have focused on coronary artery disease, type 2 diabetes,
and obesity [18–21], no study, to date, has examined
the association between single-nucleotide polymorphisms
(SNPs) of the ADIPOQ gene and SLE. Therefore, in this
study, we investigated two SNPs (rs1501299 and rs2241766)
in ADIPOQ gene and their possible association with SLE
susceptibility in the Chinese Han population.
2.MaterialsandMethods
2.1. Subjects. A total of 179 unrelated Han SLE patients
from West China Hospital, Sichuan University, were enlisted
from July 2006 to March 2009. Patients (18 males and
161 females) with an average age of 33.5 ± 13.1 years had
typical clinical SLE symptoms and were diagnosed according
to the American Rheumatism Association Criteria for SLE
classiﬁcation [22]. A total of 237 controls (24 men and 213
women) with an average age of 34.5 ±11.8 years had healthy
blood with no family history of SLE. The controls were taken
fromthesamegeographicareasasthepatients,whosegender
ratio and mean ages were matched with the SLE group. A
written informed consent was obtained from all the subjects,
and the study was performed with the approval of the ethics
committee of the Chinese Human Genome.
2.2. Genotyping of ADIPOQ. Genomic DNA was extracted
from peripheral blood cells using an extraction kit (Bioteke
Corporation, Perking, China) according to the manufac-
turer’s instructions. Polymorphisms of adiponectin gene
were identiﬁed using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) analysis. The
primer sequences and reaction conditions are shown in
Table 1. To further conﬁrm the genotyping results, PCR-
ampliﬁed DNA samples were examined by DNA sequencing.
2.3. Statistical Analysis. Genotype and allele frequencies of
rs1501299 and rs2241766 in ADIPOQ gene were compared
in two groups using a χ2 test and Fisher’s exact test. Odds
ratio(OR)and95%conﬁdenceintervals(CI)werecalculated
to assess the relative risk conferred by a particular allele and
genotype. Demographic and clinical data between groups
were analyzed by χ2 test and the Student’s t-test. Hardy-
Weinberg equilibrium was tested with a goodness of ﬁt χ2
test with one degree of freedom to compare the observed
genotype frequencies among subjects with the expected
genotype frequencies. Statistical signiﬁcance was assumed at
the P<. 05 level. The Statistical Package for Social Sciences
(SPSS 11.5 Chicago, IL, U.S.A.) was used for all of the
statistical analyses.
3. Results
The genotype and allele frequencies of rs1501299 and
rs2241766 polymorphisms are shown in Table 2. The geno-
typing results by PCR-RFLP and DNA sequencing were
100% concordant. The frequencies of the AA, AC, and
CC genotypes of rs1501299 were 5.6%, 47.5%, and 46.9%
in patients and 6.8%, 38.8%, and 54.4% in the controls,
respectively. The frequencies of the A and C alleles of
rs1501299 were 29.3% and 70.7% in patients and 26.2% and
73.8% in the controls, respectively. The frequencies of the
GG, GT, and TT genotypes of rs2241766 were 8.4%, 46.4%,
and 45.3% in patients and 8.0%, 47.7%, and 44.3% in the
controls, respectively. The frequencies of G and T alleles of
rs2241766 were 31.6% and 68.4% in patients and 31.9% and
68.1% in the controls, respectively. No signiﬁcant diﬀerence
was observed in the allele frequencies of the rs1501299 and
rs2241766 polymorphisms between thepatients andcontrols
(for rs1501299: P = .311, OR = 1.17, 95% CI: 0.86–1.59; for
rs2241766: P = .929, OR = 0.99, 95% CI: 0.74–1.33). The
same results were seen in the genotypes (Table 2).
4. Discussion
To the best of our knowledge, this is the ﬁrst study that
investigated the association between the rs2241766 and
rs1501299 polymorphisms of ADIPOQ gene and SLE. In this
study, no signiﬁcant diﬀerence was found in the distribution
of ADIPOQ gene polymorphisms between SLE patients and
controls, suggesting that ADIPOQ gene polymorphisms may
not be a signiﬁcant contributor to SLE susceptibility.
Adiponectin is an adipocyte-derived peptide expressed
exclusively in adipocytes. Adiponectines are also called
gelatin-binding protein-28 (GBP28), AdipoQ, ACRP30, or
apM1. Low plasma adiponectin concentration is associated
with metabolic disorders and an increased risk of cardio-
vascular events [23]. However, circulating adiponectin levels
have been reported to be signiﬁcantly increased in patients
with SLE, while patients with high plasma adiponectin had
poor prognosis in lupus nephritis [10, 24]. Serum levels
of adiponectin were signiﬁcantly and inversely correlated
with insulin resistance in SLE patients. Elevated levels of
adiponectin in SLE suggest the possible involvement of
adiponectin in insulin resistance and alteration of insulin
sensitivity [25].
Some studies showed that the plasma level, expression,
andbiologicaleﬀectsofadiponectinareassociatedwithpoly-
morphism in the ADIPOQ gene [26–28]. Polymorphisms
in the ADIPOQ gene have also been shown to correlateJournal of Biomedicine and Biotechnology 3
Table 1: Primer sequences and reaction conditions for genotyping adiponectin polymorphisms.
Gene Location Primer sequence Product (bp) Annealing
temperature (oC)
Restriction
enzyme
Allele (bp)
rs1501299 Intron-2 5 -GTCTAGGCCTTAGTTAATAATGAAGG-3 
106 56 STU I
A (106)
5 -GTGAGAAAGGAGATCCAGGTAA-3  C (80,26)
rs2241766 Exon-2 5 -TGGACGGAGTCCTTTGTAGG-3 
161 56 Sma I
G (134,27)
5 -TTGAGTCGTGGTTTCCTGGT-3  T(161)
Table 2: Genotype and allele frequencies of rs2241766 and rs1501299 in ADIPOQ between patients with asthma and controls.
Polymorphisms Patients Controls OR (95% CI) P
n = 179 (%) n = 237 (%)
rs1501299
genotypes
AA 10(5.6) 16(6.8) 1.00 (Ref)
AC 85(47.5) 92(38.8) 0.68(0.29–1.57) .362
CC 84(46.9) 129(54.4) 0.96(0.42–2.22) .923
alleles
A 105(29.3) 124(26.2) 1.00 (Ref)
C 253(70.7) 350(73.8) 1.17(0.86–1.59) .311
rs2241766
genotypes
GG 15(8.4) 19(8.0) 1.00 (Ref)
GT 83(46.4) 113(47.7) 1.08(0.52–2.24) .847
TT 81(45.3) 105(44.3) 1.023(0.49–2.14) .951
alleles
G 113(31.6) 151(31.9) 1.00 (Ref)
T 245(68.4) 323(68.1) 0.99(0.74–1.33) .929
For rs1501299, the AA genotype and A allele were used as reference [1.00 (ref)]; for rs2241766, the GG genotype and G were used as reference [1.00 (ref)].
with adiponectin serum levels, in which the expression of
the G allele at SNP rs2241766 was consistently higher than
the T allele among all study subjects [28]. Moreover, Hara
et al. reported that the C allele at SNP rs1501299 is inversely
associated with lower plasma adiponectin concentration in
Japanese population. Yang and Chuang reported that the
A allele at SNP rs1501299 is associated with lower serum
adiponectin concentration in Italians [23, 27]. There are
other factors that have been shown to regulate adiponectin
levels. A Mediterranean diet or a diet rich in whole grain
and fat was shown to produce increased adiponectin levels
[29, 30]. Physical activity was also shown to inﬂuence
adiponectin, and high levels of physical activity could elevate
adiponectin levels [31].
Based on these studies, we started this study with the
hypothesis that the ADIPOQ gene polymorphisms may be
one of the genetic factors that aﬀect SLE susceptibility.
However, our results show that the SNP rs2241766 and
rs1501299 in the ADIPOQ gene had no association with SLE
in the Chinese Han population. No signiﬁcant diﬀerence
was found in allele or genotype frequencies between SLE
patients and the controls in terms of the selected SNPs. This
ﬁnding is contrary with our hypothesis and suggests that this
polymorphism should be tested in groups of diﬀerent ethnic
origins.
Although deciphering the reasons for failure and ﬁnding
a positive association is diﬃcult, several possibilities should
necessarily be considered. First, SLE is a multifactorial
disease; diﬀerent individuals could be exposed to various
environmental factors and genetic susceptibility might lead
to diﬀerent results. Second, the disparity between our
results and assumptions may be due to the relatively small
number of SLE patients tested. A variation in ADIPOQ
gene may contribute to susceptibility to SLE, but the
eﬀect should be minimal. Large, varied populations of
SLE patients should be tested to avoid a statistical false
negative. Third, although the investigated SNPs (rs2241766
and rs1501299) do not aﬀect susceptibility to SLE in our
study, further research on more SNPs in the ADIPOQ
gene is needed to exclude the role of the adiponectin gene
polymorphisms as a possible susceptibility factor for SLE.
Finally, the inadequate study design, such as nonrandom
sampling, should also be considered. The possibility of
selection bias from the hospital-based case-control study is a
relevant issue. Nevertheless, the results of this study provide
additional information and motivation for further research4 Journal of Biomedicine and Biotechnology
into the association of ADIPOQ gene polymorphisms and
SLE.
In conclusion, we found that ADIPOQ gene polymor-
phisms were not associated with the risk of SLE in the Chi-
nese Hans population. Further studies are needed to explore
the complicated interaction between environmental factors
and ADIPOQ gene polymorphisms in terms of susceptibility
to SLE, especially in ethnically diverse populations.
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